A robust pipeline in pursuit of transformative therapies.

Targeting the root cause of EBV-driven disease

We are working hard to address significant unmet need in cancer and autoimmune diseases with our robust pipeline of investigational T-cell immunotherapies, paving the way for future treatments.

Tabelecleucel (tab-cel®)

Tab-cel® is under investigation for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) and is in earlier stage development for other EBV-associated diseases.

LEARN MORE arrow_forward_ios
  • RR EBV+ PTLD following SOT or HCT
    Phase 3
  • Multi-cohort: EBV+ cancers
    Phase 2
  • Nasopharyngeal carcinoma (NPC)
    Phase 1


We're developing ATA188 as an investigational off-the-shelf, allogeneic T-cell immunotherapy that aims to specifically target EBV-infected B cells and plasma cells for progressive forms of multiple sclerosis (MS).

LEARN MORE arrow_forward_ios
  • Progressive multiple sclerosis (PMS)
    Phase 2

Next-generation CAR T programs

Using a molecular toolkit of next-generation technologies, our platform can be modified to develop CAR T therapies to target a wide range of non-EBV-associated diseases.


Allogeneic CAR T targeting CD19, currently in preclinical development, leverages our EBV T-cell platform and features a next-generation 1XX co-stimulatory domain.

LEARN MORE arrow_forward_ios
  • ATA3219: B-cell malignancies


Autologous ATA2271 is in Phase 1 development and allogeneic ATA3271 is in preclinical development: both target solid tumors expressing the tumor antigen mesothelin and leverage novel next-generation 1XX co-stimulatory domain and PD-1 Dominant Negative Receptor technologies.

LEARN MORE arrow_forward_ios
  • ATA2271: Mesothelioma & other solid tumors
    Phase 1
  • ATA3271: Mesothelioma & other solid tumors

Other next-generation CAR T programs

We're tackling current limitations to CAR T therapies and developing strategies for solid tumors, acute myeloid leukemia (AML), and infectious diseases.

  • ATA3431: B-cell malignancies
  • Solid-tumor and Infectious disease CAR T programs
  • Mitch

    Mitch, living with primary progressive multiple sclerosis, MS advocate

  • Stories of Strength

    At Atara, we draw inspiration from the strength and determination of individuals who face a daily battle against serious diseases.

See what makes our technology unique.